Financial News

What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

With a market cap of $113.7 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines for oncology, hematology, immunology, cardiovascular, and neuroscience diseases. It serves patients worldwide with leading therapies such as Eliquis, Opdivo, Revlimid, Orencia, and Yervoy.

BMY is set to unveil its fiscal Q4 2025 results before the market opens on Thursday, Feb. 5. Ahead of this event, analysts expect the Princeton, New Jersey-based company to report an adjusted EPS of $1.65, down 1.2% from $1.67 in the year-ago quarter. However, it has surpassed Wall Street's bottom-line estimates in the past four quarters. 

 

For fiscal 2025, analysts project the biopharmaceutical giant to report adjusted EPS of $6.53, a surge of 467.8% from $1.15 in fiscal 2024.

www.barchart.com

BMY stock has declined 1.7% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 17.7% gain and the State Street Health Care Select Sector SPDR ETF's (XLV) 12% rise over the same period. 

www.barchart.com

Shares of Bristol Myers Squibb climbed 7.1% on Oct. 30 after the company reported stronger-than-expected Q3 2025 adjusted EPS of $1.63 and revenue rising 3% to $12.2 billion. Investor sentiment was further boosted by 18% Growth Portfolio revenue growth to $6.9 billion, driven by strong performance from its immuno-oncology portfolio, Reblozyl, Camzyos, and Breyanzi. The company also raised its full-year 2025 revenue guidance to $47.5 billion - $48 billion and updated adjusted EPS guidance to $6.40 - $6.60.

Analysts' consensus rating on BMY stock is moderately optimistic, with a "Moderate Buy" rating overall. Out of 29 analysts covering the stock, opinions include nine "Strong Buys,” one "Moderate Buy," 18 "Holds," and one "Strong Sell.” As of writing, it is trading above the average analyst price target of $56.17. 


On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.75
+0.00 (0.00%)
AAPL  352.78
+0.00 (0.00%)
AMD  504.28
+0.00 (0.00%)
BAC  50.08
+0.00 (0.00%)
GOOG  281.26
+0.00 (0.00%)
META  626.41
+0.00 (0.00%)
MSFT  517.99
+0.00 (0.00%)
NVDA  156.14
+0.00 (0.00%)
ORCL  119.09
+0.00 (0.00%)
TSLA  379.74
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback